Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies

Despite the remarkable success of chimeric antigen receptor (CAR) T-cell therapy for treating hematologic malignancies, resistance and recurrence still occur, while the markers or mechanisms underlying this resistance remain poorly understood. Here, via an unbiased genome-wide CRISPR/Cas9 screening,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xin, Chen, Deyun, Wang, Yao, Guo, Yelei, Tong, Chuan, Wei, Jianshu, Zhang, Yajing, Wu, Zhiqiang, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977349/
https://www.ncbi.nlm.nih.gov/pubmed/35370290
http://dx.doi.org/10.1038/s41392-022-00915-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977349/
https://www.ncbi.nlm.nih.gov/pubmed/35370290
http://dx.doi.org/10.1038/s41392-022-00915-1

Ejemplares similares